Torres-Quesada 2022 MitoFit Kinase

From Bioblast

Bioblast2022 banner.jpg

MitoFit Preprints         MitoFit Preprints        
Gnaiger 2019 MitoFit Preprints
Gnaiger MitoFit Preprints 2020.4
        MitoFit DOI Data Center         MitoPedia: Preprints         Bioenergetics Communications

Torres-Quesada 2022 MitoFit Kinase

Publications in the MiPMap
Torres-Quesada O, Strich S, Stefan E (2022) Kinase perturbations redirect mitochondrial function. β€” 2022-11-15 published in Bioenerg Commun 2022.13.

Β» MitoFit Preprints 2022.11.

MitoFit pdf

Kinase perturbations redirect mitochondrial function Β»Watch the presentationΒ«

MitoFit Prep 2022.11. (2022) MitoFit Prep

Abstract: Torres-Quesada 2022 Abstract Bioblast: Protein kinases take the center stage in numerous signaling pathways by phosphorylating compartmentalized protein substrates for controlling cell proliferation, cell cycle and metabolism. Kinase dysfunctions have been linked to numerous human diseases such as cancer. This has led to the development of kinase inhibitors which aim to target oncogenic kinase activities. The specificity of the cancer blockers depends on the range of targeted kinases. Therefore, the question arises of how cell-type-specific off-target effects impair the specificities of cancer drugs. Blockade of kinase activities has been shown to converge on the energetic organelle, the mitochondria. In this review, we highlight examples of selected major kinases which impact mitochondrial signaling. Further, we discuss pharmacological strategies to target kinase activities which are linked to cancer progression and redirecting mitochondrial function. Finally, we propose that cell-based recordings of mitochondrial bioenergetic states might predict off-target or identify specific on-target effects of kinase inhibitors. β€’ Keywords: Kinases, signaling, mitochondria, kinase inhibitors, cancer, drug off-target effects β€’ Bioblast editor: Doerrier C β€’ O2k-Network Lab: AT Innsbruck Oroboros

ORCID: ORCID.png Torres-Quesada Omar, ORCID.png Stefan Eduard

Labels: MiParea: Pharmacology;toxicology  Pathology: Cancer 

Organism: Human 

MitoKIN, Bioblast 2022 

Cookies help us deliver our services. By using our services, you agree to our use of cookies.